A Diabetes Drug Class Showing Up in Mast Cell Conversations: What the GLP-1 Case Series Actually Says
- Joyce Knieff, ND, LAc
- 3 days ago
- 5 min read
If you live with Mast Cell Activation Syndrome (MCAS), you have probably watched the cycle of "promising new treatment" headlines come and go. Antihistamines help, until they don't. Cromolyn helps some people and does nothing for others. Biologics work for a subset. The list of options grows, yet the unanswered question stays the same. Why does the body's immune-control system stay stuck in the "on" position? Now a familiar name from a different specialty is starting to show up in the mast cell literature: the GLP-1 receptor agonists, the same class of medications used for type 2 diabetes and weight management.
TL;DR: A 47-patient case series found that 89% of hard-to-treat MCAS patients improved on GLP-1 drugs, but with no control group, that's an early signal, not proof.
Key takeaways:
A July 2025 case series reported that 89% of 47 hard-to-treat MCAS patients improved.
It was a case series, not a controlled trial, so no placebo and no proof.
Lab and case evidence hint that GLP-1 receptors calm mast cell inflammation.
Talk to your prescriber first; lifestyle works on the same metabolic-immune axis.
What the new paper actually found
A July 2025 paper in the American Journal of the Medical Sciences, led by Dr. Lawrence Afrin and colleagues, published the first case series describing GLP-1 receptor agonists (GLP-1RAs) used in patients with hard-to-treat MCAS. The group reported on 47 patients (average age 39, range 15–71, 89% female), all with MCAS that had not been controlled by standard layered therapy. After starting a GLP-1RA (semaglutide, liraglutide, or tirzepatide depending on the case), 89% of patients showed clinical benefit across a broad range of MCAS-related symptoms.
This was a case series, not a randomized trial. That means there was no placebo group, no blinding, and no statistical comparison against another treatment. The findings are a "this is what happened" report from clinicians who tried something and watched, which is the way most novel uses of approved drugs first get documented. The authors are explicit that randomized controlled trials are needed before anyone can say how well GLP-1RAs work in MCAS, or which patients are likely to respond.
The bigger picture
The case series did not appear in a vacuum. Mechanism research has been pointing this direction for a few years. A 2023 study in the Journal of Immunology showed that GLP-1 receptors are expressed on platelets and that liraglutide reduced platelet activation and downstream inflammation in a mouse model of aspirin-exacerbated respiratory disease. A January 2026 case report in Dermatology and Therapy described two women with chronic spontaneous urticaria, a mast-cell-driven hive condition, who achieved complete remission within three weeks of starting semaglutide or tirzepatide for unrelated metabolic reasons. The remissions held for more than six months.
None of these reports prove that GLP-1RAs treat mast cell disease. What they suggest is a plausible biological story: GLP-1 receptors sit on mast cells and on related immune cells, and engaging those receptors appears to dampen the inflammatory signaling these cells produce. Whether that translates into reliable, durable symptom relief is what the field still has to figure out.
The naturopathic lens
In the clinic, I read this kind of paper through a slightly different filter. The fact that a drug developed for blood-sugar regulation is showing immune-stabilizing effects is not random. It reflects how deeply metabolism and immune signaling are wired together. People with MCAS often carry overlapping metabolic features: insulin resistance, weight changes after years of restrictive diets, blood-sugar instability that worsens flares. Those are not coincidences. They are part of the same terrain.
That framing changes how I think about what to do with this information. The medication itself is one piece. The underlying signaling is another, and a meaningful portion of that signaling is shaped by sleep, meal timing, fiber intake, post-meal movement, stress regulation, and the broader picture of metabolic health. None of those things will replace a medication for someone whose MCAS is severe, and I am not suggesting they will. They do, though, sit on the same biological axis the drug is acting on. Patients who address them in parallel, with or without pharmaceutical support, tend to do better than patients who treat MCAS as a purely "anti-mediator" project. That parallel, whole-person path is the heart of how we approach naturopathic care for histamine intolerance and MCAS.
How to apply this now
If you have MCAS and you are curious about GLP-1 receptor agonists, the next step is a conversation with the prescribing clinician who manages your case. This paper is preliminary, the evidence is early, and these medications carry their own side-effect profile that deserves a careful risk-benefit conversation tailored to you. In the meantime, the lifestyle pieces (stable meal timing, adequate fiber, gentle post-meal movement, prioritized sleep, and consistent nervous-system downregulation) are within your reach now and act on the same metabolic-immune axis. They are not a substitute for medical care. They are a foundation that makes everything else work better.
Frequently asked questions
Should I try a GLP-1 drug for my MCAS?
That's a conversation for the clinician who prescribes and manages your case, not a call to make from a blog. The evidence so far is one case series plus a couple of supporting reports, which is enough to raise the question but not enough to call it a proven treatment. If your MCAS hasn't settled on standard layered therapy, it's a reasonable thing to bring up.
How strong is the evidence right now?
Early. The main paper is a case series of 47 patients with no placebo group and no blinding, so it tells us what happened, not how well the drug works against nothing. The authors themselves say randomized trials are needed before anyone draws firm conclusions.
Who should be cautious?
GLP-1 receptor agonists carry their own side effects, and they aren't right for everyone. Anyone with a history of certain thyroid cancers, pancreatitis, or significant gut-motility issues needs a careful look at the risks and benefits. Since many people with MCAS already have GI symptoms, that conversation deserves extra attention.
What does Yggdrasil suggest for MCAS in the meantime?
The lifestyle pieces are within reach right now: stable meal timing, adequate fiber, gentle post-meal movement, prioritized sleep, and consistent nervous-system downregulation. They act on the same metabolic-immune axis the medication targets. They won't replace medical care for severe MCAS, but they tend to make everything else work better.
References
Afrin LB, Weinstock LB, Dempsey TT, et al. Utility of glucagon-like peptide-1-receptor agonists in mast cell activation syndrome. Am J Med Sci. 2025;370(4):377-382. PMID: 40675372. DOI. Original AANP link: https://pubmed.ncbi.nlm.nih.gov/40675372/
Foer D, Amin T, Nagai J, et al. Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease. J Immunol. 2023;211(12):1806-1813. PMID: 37870292. DOI.
Kwiek B, Sieczych J, Łukowska K, Ambroziak M. Improvement of Chronic Spontaneous Urticaria After GLP-1 Receptor Agonist Therapy: Report of Two Cases. Dermatol Ther (Heidelb). 2026;16(2):1419-1425. PMID: 41535531. DOI.
Castells M, Giannetti MP, Hamilton MJ, et al. Mast cell activation syndrome: Current understanding and research needs. J Allergy Clin Immunol. 2024;154(2):255-263. PMID: 38851398. DOI.
Disclaimer
This article is educational and not medical advice. It does not establish a clinician-patient relationship and is not a substitute for individualized care from your own provider. If you have MCAS, any medication decision belongs in a conversation with the clinician who knows your full picture.
Related reading
Reviewed by Joyce Knieff, ND, LAc on 2026-06-15.
If you're living with MCAS and want to explore a naturopathic approach that works alongside your medical care, book a consultation with our clinic.
Comments